Moreau, Philippe
Mateos, María-Victoria
Gonzalez Garcia, Maria Esther
Einsele, Hermann
De Stefano, Valerio
Karlin, Lionel
Lindsey-Hill, Joanne
Besemer, Britta
Vincent, Laure
Kirkpatrick, Suriya
Delforge, Michel
Perrot, Aurore
van de Donk, Niels W. C. J.
Pawlyn, Charlotte
Manier, Salomon
Leleu, Xavier
Martinez-Lopez, Joaquin
Ghilotti, Francesca
Diels, Joris
Morano, Raúl
Albrecht, Claire
Strulev, Vadim
Haddad, Imène
Pei, Lixia
Kobos, Rachel
Smit, Jennifer
Slavcev, Mary
Marshall, Alexander
Weisel, Katja
Funding for this research was provided by:
Janssen Research and Development
Legend Biotech
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 6 October 2023
Accepted: 14 November 2023
First Online: 19 December 2023
Declarations
:
: Philippe Moreau: served in a consulting/advisory role and has received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides and Sanofi. María-Victoria Mateos: served in a consulting/advisory role for AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Regeneron, Roche/Genentech, and Takeda; and has received honoraria from AbbVie/Genentech, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda. Maria Esther Gonzalez Garcia: no conflicts of interest to disclose. Hermann Einsele: received research funding or honoraria from and has served as a consultant or adviser for Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen and Sanofi. Valerio De Stefano: served on an advisory board or speakers’ bureau and received honoraria from AbbVie, Alexion, Amgen, AOP Health, Argenx, Bristol Myers Squibb, Grifols, GlaxoSmithKline, Leo Pharma, Novartis, Novo Nordisk, Sanofi, SOBI and Takeda. Lionel Karlin: has served in a consulting/advisory role for Amgen, Janssen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Sanofi, Stemline, Takeda and AbbVie; received honoraria from AbbVie, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Stemline and Takeda; has received travel expenses from Amgen, Celgene/Bristol Myers Squibb, Janssen, Sanofi and Takeda; and has an immediate family member employed by Laboratoire Aguettant. Joanne Lindsey-Hill: has received consulting fees from AbbVie and received travel expenses from Janssen. Britta Besemer: received travel, accommodations, and expenses and received honoraria from Amgen, GlaxoSmithKline and Janssen-Cilag. Laure Vincent: received funding from Janssen; received honoraria for consulting/advisory role from Bristol Myers Squibb and Janssen; received travel expenses from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi and Takeda; and has participated in a Data Safety Monitoring Board or Advisory Board for Bristol Myers Squibb, Janssen and Takeda. Suriya Kirkpatrick: received honoraria from Celgene/Bristol Myers Squibb; received travel expenses from AbbVie, Celgene/Bristol Myers Squibb and Janssen; participated in a Data Safety Monitoring Board or Advisory Board for Celgene; and served in a leadership or fiduciary role for UKONS Research MIG and UK Lung Cancer Nurses RIG. Michel Delforge: served in a consulting/advisory role for Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Stemline and Takeda; and has received research funding from Janssen. Aurore Perrot: served in a consulting role and received honoraria from AbbVie, Amgen, Celgene, Janssen-Cilag, Pfizer, Sanofi and Takeda. Niels W.C.J. van de Donk: served in a consulting/advisory role for AbbVie, Adaptive Biotechnologies, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, Servier and Takeda; and has received research funding from Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen and Novartis. Charlotte Pawlyn: received honoraria from AbbVie, Amgen, Celgene/Bristol Myers Squibb, Janssen, Pfizer, Sanofi and Takeda. Salomon Manier: received research funding from AbbVie, Celgene/Bristol Myers Squibb, Janssen, Novartis and Takeda. Xavier Leleu: held a consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb, CARsgen, Celgene, Gilead, GlaxoSmithKline, Janssen-Cilag, Karyopharm, Merck, Novartis, Oncopeptides, Roche and Takeda; received travel, accommodations and/or expenses from Takeda; and received honoraria from AbbVie, Amgen, Bristol Myers Squibb, CARsgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm, Merck, Novartis, Oncopeptides, Roche, Sanofi and Takeda. Joaquin Martinez-Lopez: has served in a consulting or advisory role, received speakers’ bureau fees and research funding from Bristol Myers Squibb, Janssen and Novartis. Francesca Ghilotti, Joris Diels, Raúl Morano, Imène Haddad, Lixia Pei, Rachel Kobos, Jennifer Smit, Mary Slavcev and Alexander Marshall: employed by Janssen. Claire Albrecht and Vadim Strulev: employed by and own stock in Janssen. Katja Weisel: served as a consultant for and received honoraria from Adaptive Biotechnologies, Karyopharm and Takeda; has received honoraria from Roche; and has received honoraria and served as a member on boards of directors and/or advisory committees for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncopeptide and Sanofi.
: Data analyzed in this study were received from the MajesTEC-1, LocoMMotion, and MoMMent studies. MajesTEC-1 was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. An independent ethics committee or institutional review board at each study center approved the study protocol. The LocoMMotion and MoMMent studies were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. An independent ethics committee/institutional review board at each center approved the study protocol, listed in the Supplementary Material.